490 related articles for article (PubMed ID: 32431173)
1. Assays and technologies for developing proteolysis targeting chimera degraders.
Liu X; Zhang X; Lv D; Yuan Y; Zheng G; Zhou D
Future Med Chem; 2020 Jun; 12(12):1155-1179. PubMed ID: 32431173
[TBL] [Abstract][Full Text] [Related]
2. Recent advances in targeted protein degraders as potential therapeutic agents.
Yang N; Kong B; Zhu Z; Huang F; Zhang L; Lu T; Chen Y; Zhang Y; Jiang Y
Mol Divers; 2024 Feb; 28(1):309-333. PubMed ID: 36790583
[TBL] [Abstract][Full Text] [Related]
3. PROTACs: past, present and future.
Li K; Crews CM
Chem Soc Rev; 2022 Jun; 51(12):5214-5236. PubMed ID: 35671157
[TBL] [Abstract][Full Text] [Related]
4. Small-Molecule Degraders beyond PROTACs-Challenges and Opportunities.
Kastl JM; Davies G; Godsman E; Holdgate GA
SLAS Discov; 2021 Apr; 26(4):524-533. PubMed ID: 33632029
[TBL] [Abstract][Full Text] [Related]
5. E3 Ligase Ligands for PROTACs: How They Were Found and How to Discover New Ones.
Ishida T; Ciulli A
SLAS Discov; 2021 Apr; 26(4):484-502. PubMed ID: 33143537
[TBL] [Abstract][Full Text] [Related]
6. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy.
Li X; Song Y
J Hematol Oncol; 2020 May; 13(1):50. PubMed ID: 32404196
[TBL] [Abstract][Full Text] [Related]
7. Kinetic Detection of E3:PROTAC:Target Ternary Complexes Using NanoBRET Technology in Live Cells.
Mahan SD; Riching KM; Urh M; Daniels DL
Methods Mol Biol; 2021; 2365():151-171. PubMed ID: 34432243
[TBL] [Abstract][Full Text] [Related]
8. PROTACs: Current Trends in Protein Degradation by Proteolysis-Targeting Chimeras.
Madan J; Ahuja VK; Dua K; Samajdar S; Ramchandra M; Giri S
BioDrugs; 2022 Sep; 36(5):609-623. PubMed ID: 36098871
[TBL] [Abstract][Full Text] [Related]
9. PROteolysis TArgeting Chimeras (PROTACs) as emerging anticancer therapeutics.
Khan S; He Y; Zhang X; Yuan Y; Pu S; Kong Q; Zheng G; Zhou D
Oncogene; 2020 Jun; 39(26):4909-4924. PubMed ID: 32475992
[TBL] [Abstract][Full Text] [Related]
10. Lessons in PROTAC Design from Selective Degradation with a Promiscuous Warhead.
Bondeson DP; Smith BE; Burslem GM; Buhimschi AD; Hines J; Jaime-Figueroa S; Wang J; Hamman BD; Ishchenko A; Crews CM
Cell Chem Biol; 2018 Jan; 25(1):78-87.e5. PubMed ID: 29129718
[TBL] [Abstract][Full Text] [Related]
11. Optimization of PROTAC Ternary Complex Using DNA Encoded Library Approach.
Chen Q; Liu C; Wang W; Meng X; Cheng X; Li X; Cai L; Luo L; He X; Qu H; Luo J; Wei H; Gao S; Liu G; Wan J; Israel DI; Li J; Dou D
ACS Chem Biol; 2023 Jan; 18(1):25-33. PubMed ID: 36606710
[TBL] [Abstract][Full Text] [Related]
12. Proteolysis-targeting chimeras mediate the degradation of bromodomain and extra-terminal domain proteins.
Yang Y; Wu Z; Chen P; Zheng P; Zhang H; Zhou J
Future Med Chem; 2020 Sep; 12(18):1669-1683. PubMed ID: 32893690
[TBL] [Abstract][Full Text] [Related]
13. Modeling the CRL4A ligase complex to predict target protein ubiquitination induced by cereblon-recruiting PROTACs.
Bai N; Riching KM; Makaju A; Wu H; Acker TM; Ou SC; Zhang Y; Shen X; Bulloch DN; Rui H; Gibson BW; Daniels DL; Urh M; Rock BM; Humphreys SC
J Biol Chem; 2022 Apr; 298(4):101653. PubMed ID: 35101445
[TBL] [Abstract][Full Text] [Related]
14. Quantitative Live-Cell Kinetic Degradation and Mechanistic Profiling of PROTAC Mode of Action.
Riching KM; Mahan S; Corona CR; McDougall M; Vasta JD; Robers MB; Urh M; Daniels DL
ACS Chem Biol; 2018 Sep; 13(9):2758-2770. PubMed ID: 30137962
[TBL] [Abstract][Full Text] [Related]
15. PROTAC degraders as chemical probes for studying target biology and target validation.
Němec V; Schwalm MP; Müller S; Knapp S
Chem Soc Rev; 2022 Sep; 51(18):7971-7993. PubMed ID: 36004812
[TBL] [Abstract][Full Text] [Related]
16. Perspectives on the development of first-in-class protein degraders.
Rambacher KM; Calabrese MF; Yamaguchi M
Future Med Chem; 2021 Jul; 13(14):1203-1226. PubMed ID: 34015962
[TBL] [Abstract][Full Text] [Related]
17. Monitoring and deciphering protein degradation pathways inside cells.
Daniels DL; Riching KM; Urh M
Drug Discov Today Technol; 2019 Apr; 31():61-68. PubMed ID: 31200861
[TBL] [Abstract][Full Text] [Related]
18. Recent advances in epigenetic proteolysis targeting chimeras (Epi-PROTACs).
Tomaselli D; Mautone N; Mai A; Rotili D
Eur J Med Chem; 2020 Dec; 207():112750. PubMed ID: 32871345
[TBL] [Abstract][Full Text] [Related]
19. The rise of covalent proteolysis targeting chimeras.
Gabizon R; London N
Curr Opin Chem Biol; 2021 Jun; 62():24-33. PubMed ID: 33549806
[TBL] [Abstract][Full Text] [Related]
20. Expanding the ligand spaces for E3 ligases for the design of protein degraders.
Shah Zaib Saleem R; Schwalm MP; Knapp S
Bioorg Med Chem; 2024 May; 105():117718. PubMed ID: 38621319
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
